Search

Displaying results 3531 - 3540 of 10000 in total
  1. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … [A273848] In order to further reduce the risk of toxicities and improve efficacy, penpulimab was designed with Fc mutations in order to eliminate Fc receptor and complement-mediated effector function,

  2. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  3. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. … Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo

    Products: Paraldehyde Inj Bp 100%
  4. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    [L45633,L45658] It was subsequently approved in the EU in November of the same year. [L52745] … [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.

  5. Drug

    Farletuzumab ecteribulin

    go.drugbank.com/drugs/DB18857
    Investigational

    Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), … a Folate Receptor Alpha (Frα)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).

  6. Drug

    Growth hormone-releasing peptide 1

    go.drugbank.com/drugs/DB19259
    Investigational

    , and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis). … Growth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics

  7. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation … Coagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX.

  8. Drug

    Terpin hydrate

    go.drugbank.com/drugs/DB13163
    ApprovedWithdrawn

    It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate … Terpin hydrate is an expectorant, commonly used to loosen mucus and ease congestion in patients presenting with acute or chronic bronchitis, and related pulmonary conditions.

  9. Drug

    Relmapirazin

    go.drugbank.com/drugs/DB19130
    Investigational

    Relmapirazin is under investigation in clinical trial NCT05425719 (Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the Medibeacon Transdermal GFR Measurement System in Evaluation of Kidney Function … in Normal and Renal Compromised Subjects).

    Synonyms: D-serine, n,n'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis-, N,n'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis(d-serine)
  10. Drug

    Tarloxotinib

    go.drugbank.com/drugs/DB14944
    Investigational

    Tarloxotinib is under investigation in clinical trial NCT03743350 (NSCLC Exon 20 or HER2-activating Mutations).